Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure

Clinical Infectious Diseases

Volumn 38, Issue 8, 2004, Pages 1049-1055

  Whitener, Cynthia J ^a   Park, Sarah Y ^b   Browne, Fred A ^a   Parent, Leslie J ^a   Julian, Kathleen ^a   Bozdogan, Bülent ^a   Appelbaum, Peter C ^a   Chaitram, Jasmine ^b   Weigel, Linda M ^b   Jernigan, John ^c   McDougal, Linda K ^c   Tenover, Fred C ^c   Fridkin, Scott K ^c  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; LINEZOLID; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHIZOLE; TAZOBACTAM; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN; ANTIINFECTIVE AGENT; METICILLIN;

AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; FOOT ULCER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MALE; OSTEOMYELITIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; DRUG EFFECT; FOLLOW UP; INFECTION CONTROL; LEGAL ASPECT; MICROBIOLOGICAL EXAMINATION; OUTCOME ASSESSMENT;

AGED; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FOLLOW-UP STUDIES; HUMANS; INFECTION CONTROL; MALE; METHICILLIN; MICROBIAL SENSITIVITY TESTS; OUTCOME ASSESSMENT (HEALTH CARE); STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 2342507884     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/382357     Document Type: Article

References (43)

1. Lowry FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
2. Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998; 27:245-51.
3. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29:245-52.
4. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36:131-9.
5. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157-61.
6. Uttley AH, Collins CH, Naidoo J, et al. Vancomycin-resistant enterococci. Lancet 1988; 1:57-8.
7. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72:195-8.
8. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:624-6.
9. Oliveira GA, Dell'Aquila AM, Masiero RL, et al. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol 2001; 22:443-8.
10. Krzyszton-Russjan J, Gniadkowski M, Polowniak-Pracka H, Hagmajer E, Hryniewicz W. The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland. J Antimicrob Chemother 2002; 50:1065-9.
11. Denis O, Nonhoff C, Byl B, Knoop C, Bobin-Dubreux S, Struelens MJ. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiologic and clinical features. J Antimicrob Chemother 2002; 50:383-91.
12. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340:493-501.
13. Rotun SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999; 5:147-9.
14. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48:1165-7.
15. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32:108-15.
16. Hageman JC, Pegues DA, Jepson C, et al. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg Infect Dis 2001; 7:1023-5.
17. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42:199-209.
18. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179:2557-66.
19. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1:147-55.
20. Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41:5-14.
21. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002; 56:657-75.
22. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved standard M7-A5. Wayne, PA: NCCLS, 2000.
23. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7.
24. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.
25. Kloos W, Bannerman TL. Staphylococcus and micrococcus. In: Murray PR, ed. Manual of clinical microbiology. Washington, DC: ASM Press, 1999:264-82.
26. Vannuffel P, Gigi J, Ezzedine H, et al. Specific detection of methicillin-resistant Staphylococcus species by multiplex PCR. J Clin Microbiol 1995; 33:2864-967.
27. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide-resistant enterococci from US hospitals. Antimicrob Agents Chemother 1993; 37:2311-7.
28. Ostrowsky BE, Clark NC, Thauvin-Eliopoulos C, et al. A cluster of vanD vancomycin-resistant Enterococcus faecium: molecular characterization and clinical epidemiology. J Infect Dis 1999; 180:1177-85.
29. Bannerman TL, Hancock GA, Tenover FC, Miller JM. Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J Clin Microbiol 1995; 33:551-5.
30. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-9.
31. Garner JS. Guideline for isolation precautions in hospitals, HICPAC. Infect Control Hosp Epidemiol 1996; 17:53-80.
32. Garner JS. Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices, HICPAC. Am J Infect Control 1996; 24:24-31.
33. Garner JS, Favero MS. Guideline for handwashing and hospital environmental control. HHS publication no. 99 1117. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 1985.
34. Woodford N. Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist 2001; 7:229-36.
35. Franchi D, Climo MW, Wong AH, Edmond MB, Wenzel RP. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci. Clin Infect Dis 1999; 29:1566-8.
36. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41:5113-20.
37. Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-level resistance to glycopeptide LY33328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother 1999; 43:1875-80.
38. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant enterococcus. Emerg Infect Dis 2002; 8:802-7.
39. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997; 46:626-28, 635.
40. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995; 44:1-13.
41. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36:1020-7.
42. Tenover FC, Weigel LM, Appelbaum PC, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48:275-80.
43. Centers for Disease Control and Prevention. Investigation and control of vancomycin-intermediate and -resistant Staphylococcus aureus (VISA/VRSA): a guide for health departments and infection control personnel. Available at: http://www.cdc.gov/ncidod/hip/vanco/Vanco .htm. Accessed on 16 March 2004.